Halloum W, Dughem YA, Beier D, Pellesi L (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review
[DOI] [PubMed] [Google Scholar] 119.Owen PJ, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH
If it is a standard powder, the absorption may be too low to see skin results
Sources: EMBRAZE Phase 2 press release Scholar Rock, June 2025 EMBRAZE full publication Nature Medicine, 2026 BELIEVE trial: bimagrumab + semaglutide HCPLive, May 2026 Lilly pauses bimagrumab trial BioPharma Dive, Sept
Clinical trials of semaglutide show average weight loss of 1015% of body weight over 68 weeks at therapeutic doses
It works well on areas that hold loose skin